| 1. |
- Zhang, Kaicheng, et al.
(författare)
-
SN 2014J in M82 : new insights on the spectral diversity of Type Ia supernovae
- 2018
-
Ingår i: Monthly notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 481:1, s. 878-893
-
Tidskriftsartikel (refereegranskat)abstract
- We present extensive spectroscopic observations for one of the closest Type Ia supernovae (SNe Ia), SN 2014J discovered in M82, ranging from 10.4 d before to 473.2 d after B-band maximum light. The diffuse interstellar band features detected in a high-resolution spectrum allow an estimate of line-of-sight extinction as A(v) similar to 1.9 +/- 0.6 mag. Spectroscopically, SN 2014J can be put into the high-velocity (HV) subgroup in Wang's classification with a velocity of Si II lambda 6355 at maximum light of upsilon(0) = 1.22 +/- 0.01 x 10(4) km s(-1) but has a low velocity gradient (LVG, following Benetti's classification) of (v) over bar = 41 +/- 2 km s(-1) d(-1), which is inconsistent with the trend that HV SNe Ia generally have larger velocity gradients. We find that the HV SNe Ia with LVGs tend to have relatively stronger Si III (at similar to 4400 angstrom) absorptions in early spectra, larger ratios of S II lambda 5468 to S II lambda 5640, and weaker Si II 5972 absorptions compared to their counterparts with similar velocities but high velocity gradients. This shows that the HV+ LVG subgroup of SNe Ia may have intrinsically higher photospheric temperature, which indicates that their progenitors may experience more complete burning in the explosions relative to the typical HV SNe Ia.
|
|
| 2. |
- Hua, Sha, et al.
(författare)
-
Influence of APOA5 locus on the treatment efficacy of three statins : Evidence from a randomized pilot study in Chinese subjects
- 2018
-
Ingår i: Frontiers in Pharmacology. - : Frontiers Media SA. - 1663-9812. ; 9:APR
-
Tidskriftsartikel (refereegranskat)abstract
- Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is APOA5, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored APOA5-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5-10 mg/day), atorvastatin (10-20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the APOA5 promoter SNP rs662799 (-1131T > C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL cholesterol were influenced by the APOA5 genotype in all three treatment groups. By contrast, changes in HDL cholesterol, and triglycerides were only affected by the APOA5 genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results suggest that future studies may need to consider stratifying subjects not only by genetic background but also by prescribed statin type.
|
|
